Literature DB >> 15937431

Anti-hu paraneoplastic syndrome presenting as bilateral sixth cranial nerve palsies.

Tarek Hammam1, Robert M McFadzean, James W Ironside.   

Abstract

A 62-year-old woman presented with diplopia caused by bilateral sixth cranial nerve palsies. Two weeks later, she had bulbar weakness and ataxia. Brain magnetic resonance imaging showed non-specific abnormalities and spinal fluid was acellular but contained an elevated protein and oligoclonal bands. A paraneoplastic screen showed anti-Hu antibodies. Her clinical condition improved with immunoglobulin and systemic corticosteroid treatment. Breast cancer was diagnosed 21 months later by mammography but there were no metastases detected. Four and half years after the onset of her diplopia, she died of diffuse metastatic breast cancer. This is the first reported case of anti-Hu paraneoplastic brain stem encephalitis presenting with sixth cranial nerve palsies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15937431     DOI: 10.1097/01.wno.0000165103.01237.f1

Source DB:  PubMed          Journal:  J Neuroophthalmol        ISSN: 1070-8022            Impact factor:   3.042


  3 in total

1.  Isolated cranial mononeuropathy: an unusual initial presentation and disease progression of metastatic carcinoma of the breast.

Authors:  Ming Y Lim; Sindu Chandramouleeswaran; Timothy M Zagar; Debra Budwit; Carey K Anders
Journal:  J Clin Oncol       Date:  2013-05-13       Impact factor: 44.544

2.  Clinical and organizational factors in the initial evaluation of patients with lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.

Authors:  David E Ost; Sai-Ching Jim Yeung; Lynn T Tanoue; Michael K Gould
Journal:  Chest       Date:  2013-05       Impact factor: 9.410

Review 3.  Ocular side effects of biological agents in oncology: what should the clinician be aware of?

Authors:  Tobias Hager; B Seitz
Journal:  Onco Targets Ther       Date:  2013-12-24       Impact factor: 4.147

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.